LinkFINANCING & FUNDING: Warmer Climate, but VCs Still Wary
A resolution to the political tug-of-war over the federal budget and agency funding can be expected to warm the long chilly climate for financing biopharma and other life sciences companies in the U.S., G. Steven Burrill, CEO of Burrill & Company, predicted late last month. He expects the industry to raise $100 billion in capital in 2013, “with financings heavily weighted to the large companies and to the use of debt.”
Tuesday, January 8, 2013
GEN's 7 biotech trends for 2013
A good summary by Alex Phillipidis over at GEN:
